Does Fingolimod Interact with Ocrelizumab And Hyaluronidase?
CDI records a moderate classification for Fingolimod and Ocrelizumab And Hyaluronidase. The stored summary is: Concomitant use may increase risk of additive immunosuppressive effects due to prolonged immune effects of fingolimod. Consider duration and mode of action when switching to ocrelizumab. The mechanism involves additive immunosuppressive effects. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Fingolimod Class
- Sphingosine 1-phosphate Receptor Modulator
- Ocrelizumab And Hyaluronidase Class
- Endoglycosidase
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Additive immunosuppressive effects
What To Tell Your Doctor or Pharmacist
If you are taking Fingolimod and your doctor is considering prescribing Ocrelizumab And Hyaluronidase (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider